Industry

ATLANTA–(BUSINESS WIRE)–Healthcare remains the most targeted industry for cyberattacks, with third-party suppliers implicated in the majority of major breaches. In fact, supplier-related incidents accounted for over 55% of healthcare breaches in 2024, and the average cost of a healthcare data breach exceeded $10 million. For organizations entrusted with protected health information (PHI) and critical patient … [Read more…]

— In the Largest Clinical Trial Conducted in Autoimmune PAP, Molgramostim Inhalation Solution (Molgramostim) Reduced Surfactant Burden and Improved Pulmonary Gas Transfer, Respiratory Health-Related Quality of Life, and Patient Functionality — LANGHORNE, Pa.–(BUSINESS WIRE)–Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the results from the … [Read more…]

CHICAGO–(BUSINESS WIRE)–Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the “Board”) has approved an amendment to extend the Company’s existing Stockholder Rights Plan for an additional six months (the “Rights Plan”). The Rights Plan, adopted on February 26, 2024, was due to expire at … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “mRNA Synthesis Raw Materials – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for mRNA Synthesis Raw Materials was estimated at US$1.7 Billion in 2024 and is projected to reach US$2.0 Billion by 2030, growing at a CAGR of 2.5% from 2024 to 2030. This comprehensive report … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Stuttering Market – A Global and Regional Analysis: Focus on Country and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering. The global Stuttering market is highly competitive, with several leading companies driving innovation and market growth. AstraZeneca, through its acquisition of Alexion Pharmaceuticals, is a major player, offering … [Read more…]

CRANBURY, N.J.–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s pivotal Phase 2 trial of RP-A501 for the treatment of … [Read more…]

Transforms present balance sheet with significant reduction in liabilities Largest shareholder is long-term strategic investor NEW YORK–(BUSINESS WIRE)–$TNFA–TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 … [Read more…]

Anaergia anticipates C$184 million in revenue from the Agreement TREVIGLIO, Italy & BURLINGTON, Ontario–(BUSINESS WIRE)–Anaergia Inc. (“Anaergia”, the “Company”, “us”, or “our”) (TSX:ANRG; OTCQX:ANRGF), through its subsidiary Anaergia S.r.l., has signed a Binding Agreement (“Agreement”) with a leading Spanish company specializing in renewable gas infrastructure projects. Under the terms of the Agreement, Anaergia will provide … [Read more…]

An AI-powered solution that automates prior authorizations from eligibility detection to appeals, helping health systems reduce admin burden, accelerate patient care, and prevent denials. SAN FRANCISCO–(BUSINESS WIRE)–Innovaccer Inc., a leading healthcare AI company, today announced the launch of Flow Auth, an AI-powered prior authorization solution, that is part of Flow by Innovaccer, the company’s revenue … [Read more…]

STOCKHOLM–(BUSINESS WIRE)–Xspray Pharma (Nasdaq Stockholm: XSPRAY) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate XS003 (nilotinib) for the treatment of chronic myeloid leukemia (CML). The application is based on successful studies demonstrating bioequivalence with the reference product Tasigna®. XS003 demonstrates the lowest documented food … [Read more…]